Apollo Therapeutics is a biopharmaceutical company, rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. We identify and develop pre-clinical and clinical stage assets with strong biological hypotheses and the potential to become meaningful new treatment options. Our team combines ‘drug hunters’ and deep subject matter experts who together are building an expansive and de-risked portfolio in oncology, major inflammatory disorders, and rare diseases.

Backed by leading specialist investors including Patient Square Capital and Rock Springs Capital, we have operations in Cambridge, UK, and Boston, USA.

Apollo Therapeutics has core innovation sourcing and drug discovery collaborations with five of the world’s leading universities; University of Cambridge, University College London, Imperial College London, Kings College London and the Institute of Cancer Research (ICR).

With our university partners, we have built translational leadership in three core areas of biological focus – immunology, cell signaling, and cell stress responses and metabolism.

Connect with Us

Interested in learning more about Apollo? Contact us today. We look forward to hearing from you.